COO COOPER COMPANIES, INC.
Price Chart
Executive Summary
CooperCompanies reported Q2 2026 record revenue of $1.082B (+8% YoY, +5% organic) and Non-GAAP EPS of $1.21 (+26% YoY), beating consensus. However, GAAP EPS was -$0.40 due to a $271.6M net litigation charge to resolve substantially all claims from a 2023 CooperSurgical fertility media recall. FY2026 revenue guidance was lowered to $4.285-$4.321B (organic growth 3.5%-4.5%), down from prior $4.306-$4.346B, while Non-GAAP EPS guidance of $4.58-$4.66 was reaffirmed. The litigation resolution removes a major overhang but the revenue guidance cut tempers the outlook.
Key Financial Metrics
Actionable Insight
The litigation resolution removes a significant overhang and allows management to proceed with its strategic review of CooperSurgical, which could unlock value. However, the FY2026 revenue guidance cut (organic growth 3.5%-4.5% vs prior 4.5%-5.5%) signals deceleration. Monitor the strategic review outcome and next quarter's organic growth trajectory for signs of stabilization.
Key Facts
- Q2 2026 revenue of $1.082B, up 8% reported and 5% organically YoY
- Non-GAAP diluted EPS of $1.21, up 26% YoY, beating consensus of $1.10
- GAAP diluted EPS of $(0.40) vs $0.44 YoY, driven by $271.6M net litigation charge
- Recorded $324.1M accrued litigation liability, partially offset by $52.5M expected insurance recoveries
- Settlement agreements cover over 95% of claimants from CooperSurgical fertility media recall
- FY2026 total revenue guidance lowered to $4.285-$4.321B (organic growth 3.5%-4.5%) from prior $4.306-$4.346B
- FY2026 Non-GAAP diluted EPS guidance reaffirmed at $4.58-$4.66
- CooperVision revenue $723.5M (+8% reported, +4% organic); CooperSurgical $358.0M (+8% reported, +6% organic)
- Operating cash flow $182.8M, FCF $96.4M; repurchased $13.1M in stock during Q2
- Long-term FCF objective exceeding $2.2B for FY2026-2028 reaffirmed
Financial Impact
$271.6M net pre-tax litigation charge ($324.1M gross liability less $52.5M insurance recoveries) recorded in Q2 2026 SG&A; FY2026 revenue guidance reduced by ~$21M at midpoint
Risk Factors
- Lowered FY2026 revenue guidance implies slowing organic growth, particularly in CooperVision Asia Pacific (-6% YoY)
- Remaining ~5% of claimants not yet settled could lead to additional costs
- Tariff exposure and FX headwinds continue to pressure margins
- CooperSurgical strategic review outcome uncertain — could result in divestiture or restructuring
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040823 |
| Document: coo-20260604.htm | 0001628280-26-040823 |
| Document: 0001628280-26-040823-index-headers.html | 0001628280-26-040823 |
| Document: 0001628280-26-040823-index.html | 0001628280-26-040823 |
| Document: 0001628280-26-040823.txt | 0001628280-26-040823 |
| 8-K Data (Synthetic) | 0001628280-26-040823 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
2d ago
|
8-K
| — | awaiting T+60 | — | — |
|
Jun 4, 2026
2d ago
|
Press Release
| — | awaiting T+60 | — | — |
|
Mar 5, 2026
13w ago
|
8-K
| $76.36 $60.19 | ▼ −21.18% | ▼ −33.96% | $67.34 (−11.82%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $76.36 $60.19 | ▼ −21.18% | ▼ −33.96% | $67.34 (−11.82%) |
|
Feb 24, 2026
14w ago
|
DEFA14A
| $83.38 $61.75 | ▼ −25.95% | ▼ −32.90% | $67.34 (−19.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access